UT Southwestern Medical Center’s Ted Laetsch is the lead author of a study focusing on how a drug called larotrectinib can be used to treat pediatric cancer patients. (UT Southwestern Photo)
Two clinical studies have provided evidence suggesting that an experimental precision-medicine drug called larotrectinib can fight soft-tissue tumors regardless of the patient’s age or the type of tumor.
Seattle Children’s Hospital participated in both studies.
Get the full story on GeekWire.
This entry was posted in GeekWire
and tagged Cancer
. Bookmark the permalink